Mirum Wins FDA Nod for FOP Pill, Challenging Regeneron

Media partner

PHARMA REGULATION · RARE DISEASE APPROVAL · SEPTEMBER 26, 2026 · USA

Three approved treatments now exist for fibrodysplasia ossificans progressiva (FOP), a genetic disorder in which soft tissues progressively convert to bone — and two of them arrived within five weeks of each other. The U.S. Food and Drug Administration cleared zilurgisertib (Atebrioz), developed by Mirum Pharmaceuticals, a Foster City, California-based rare-disease company listed on Nasdaq as MIRM, on September 25, 2026, for patients aged 12 and older, according to Fierce Pharma. The approval follows the FDA’s August 2026 clearance of garetosmab (Pasatru) from Regeneron, and comes roughly three years after Ipsen’s palovarotene (Sohonos) became the first drug approved for the condition in 2023.

The compressed timeline matters structurally. At the start of summer 2026, according to Fierce Pharma, only Sohonos was on the U.S. market. The FOP patient population is estimated at roughly 900 worldwide and approximately 300 in the United States, per reporting by both Fierce Pharma and BioPharma Dive — a pool so small that two new entrants arriving simultaneously creates an unusually concentrated competitive dynamic in a market with almost no historical commercial precedent.

A market built on unmet need, not on prior commercial success

Mirum’s entry into FOP traces to an April 2026 licensing agreement with Incyte, a biopharmaceutical company, under which Mirum paid $16 million upfront for global commercial rights to zilurgisertib, with additional regulatory and sales milestones potentially to follow, according to Fierce Pharma. The relatively modest upfront payment — by rare-disease licensing standards — may reflect the asset’s earlier-stage commercial profile at the time of the deal, though the terms of any milestone structure have not been publicly disclosed.

Zilurgisertib works by blocking activin receptor-like kinase 2 (ALK2), a receptor that is overactive in people with FOP and drives the downstream signaling that initiates abnormal bone growth in muscles and ligaments, per Fierce Pharma. The FDA’s approval was based on the phase 2 Progress trial, in which 63 adults and adolescents took zilurgisertib for 24 weeks, according to Fierce Pharma. The trial was funded by Incyte; at week 24, mean total new heterotopic ossification lesion volume decreased by 3.2 cm³ with zilurgisertib versus an increase of 24.6 cm³ with placebo, according to Mirum and Incyte.

Regeneron’s garetosmab targets a different mechanism — it is a monoclonal antibody that blocks activin A, the protein believed to trigger the FOP disease process — and is administered intravenously once monthly. In the phase 3 Optima trial, which enrolled 63 adults with FOP, both the 10 mg/kg and 3 mg/kg doses of garetosmab reduced new heterotopic ossification lesions compared to placebo, according to Regeneron: 2 new lesions among 23 patients on the 10 mg/kg dose and 1 new lesion among 19 patients on the 3 mg/kg dose, versus 19 new lesions among 21 patients on placebo over 56 weeks. The 10 mg/kg dose also reduced clinician-assessed disease flare-ups to 9 over 56 weeks, compared with 66 in the placebo group, per Regeneron. The Optima trial was sponsored by Regeneron.

The two drugs have not been tested head-to-head, and no direct comparative efficacy data exist. The distinction that may carry the most commercial weight is route of administration: zilurgisertib is a once-daily oral tablet, while garetosmab requires a 60-minute intravenous infusion at a clinical site once monthly. For a patient population that can experience sudden, unpredictable loss of mobility, the logistical burden of infusion visits is a non-trivial consideration.

Pricing and payer coverage remain the open variables

Regeneron has disclosed a list price for garetosmab of approximately $1.4 million per patient per year on average, based on clinical-study enrollees, with a range of roughly $693,000 to $2.1 million depending on body weight and dose, according to a Regeneron spokesperson cited by BioPharma Dive. Mirum has not publicly disclosed a list price for zilurgisertib as of the date of this article’s publication. No analyst peak-sales estimate for zilurgisertib has been published in the sources reviewed here.

The payer coverage picture for both drugs remains unsettled. Medicare and commercial insurer formulary decisions for newly approved ultra-rare disease therapies typically follow approval by weeks to months, and no coverage determination for zilurgisertib has been announced. For garetosmab, coverage terms have not been detailed in public sources. The size of the addressable patient pool — approximately 300 in the United States — means that even full commercial penetration would represent a narrow revenue base by pharma standards, though per-patient pricing at the levels Regeneron has set could make the market commercially meaningful for a company of Mirum’s scale.

The named incumbent whose position is most directly affected is Ipsen’s palovarotene (Sohonos), which had the U.S. FOP market to itself from its 2023 approval until August 2026. BioPharma Dive noted that Sohonos has generated disappointing sales since launch and that its approval came despite questions about its benefits and safety raised by FDA scientists at the time — including concerns that patients on the drug might be more likely than placebo recipients to experience inflammatory flare-ups preceding abnormal bone formation. Ipsen reported Sohonos sales of €21 million (about $24 million) in the first half of 2026, according to BioPharma Dive.

Mirum CEO Chris Peetz told Fierce Pharma that over the past five years, the company estimated more FOP patients were enrolled in clinical studies than were on commercial drugs — a characterization that, if accurate, points to a structural gap between diagnosis, trial participation, and treatment uptake that approval alone does not close. Converting trial participants and newly diagnosed patients into commercial users will require patient identification infrastructure and specialist engagement that Mirum, a company whose prior approvals have been concentrated in rare pediatric liver diseases, will need to build or adapt for a different disease community.

The principal friction is not competitive but operational. FOP is diagnosed by a small number of specialist centers, and the patient population is geographically dispersed. Reaching approximately 300 U.S. patients — many of whom may already be in clinical follow-up with Regeneron or Ipsen — requires a field presence calibrated to a disease where the treating physician community is narrow. No Latin American regulatory filing for zilurgisertib has been identified in the sources reviewed; the mechanism that would apply in Brazil is a priority review for rare diseases by the Agência Nacional de Vigilância Sanitária (ANVISA), and in Mexico a Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) reliance pathway on a recognized foreign authority, though neither process has been initiated publicly as of this writing.

The deeper structural question is whether three approved therapies in a population of roughly 300 U.S. patients accelerates diagnosis — by raising specialist awareness and creating commercial incentives for patient identification — or simply redistributes a fixed, undercounted pool. If Peetz’s observation about trial enrollment outpacing commercial use reflects a latent diagnosed population rather than a truly untreated one, the commercial ceiling for all three products is lower than the approval count implies.

Why this is relevant

Sources: Mirum Pharmaceuticals and Incyte · Fierce Pharma · Regeneron · BioPharma Dive